[go: up one dir, main page]

EA200200207A1 - Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы - Google Patents

Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы

Info

Publication number
EA200200207A1
EA200200207A1 EA200200207A EA200200207A EA200200207A1 EA 200200207 A1 EA200200207 A1 EA 200200207A1 EA 200200207 A EA200200207 A EA 200200207A EA 200200207 A EA200200207 A EA 200200207A EA 200200207 A1 EA200200207 A1 EA 200200207A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cgrp
inhibitors
menopause
tides
relief
Prior art date
Application number
EA200200207A
Other languages
English (en)
Other versions
EA007531B1 (ru
Inventor
Хенри Додс
Клаус Рудольф
Вольфганг Эберлайн
Вольфхард Энгель
Original Assignee
Бёрингер Ингельхайм Фарма Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Кг filed Critical Бёрингер Ингельхайм Фарма Кг
Publication of EA200200207A1 publication Critical patent/EA200200207A1/ru
Publication of EA007531B1 publication Critical patent/EA007531B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описано применение антагонистов CGRP и ингибиторов высвобождения CGRP для профилактики приливов в период менопаузы, а также описаны соответствующие лекарственные средства, содержащие в качестве действующего вещества один или несколько антагонистов CGRP и/или ингибиторов высвобождения CGRP, и способ получения таких лекарственных средств.Отчет о международном поиске был опубликован 2002.02.07.
EA200200207A 1999-08-10 2000-08-05 Применение антагонистов cgrp для устранения приливов в период менопаузы EA007531B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
PCT/EP2000/007613 WO2001010425A2 (de) 1999-08-10 2000-08-05 Verwendung von cgrp-antagonisten und cgrp-release-hemmern zur bekämpfung menopausaler hitzewallungen

Publications (2)

Publication Number Publication Date
EA200200207A1 true EA200200207A1 (ru) 2002-08-29
EA007531B1 EA007531B1 (ru) 2006-10-27

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200207A EA007531B1 (ru) 1999-08-10 2000-08-05 Применение антагонистов cgrp для устранения приливов в период менопаузы

Country Status (32)

Country Link
EP (1) EP1207884B1 (ru)
JP (1) JP2003506403A (ru)
KR (1) KR100713573B1 (ru)
CN (1) CN1166361C (ru)
AR (1) AR025078A1 (ru)
AT (1) ATE281168T1 (ru)
AU (1) AU777709B2 (ru)
BG (1) BG65366B1 (ru)
BR (1) BR0013009A (ru)
CA (1) CA2378428C (ru)
CZ (1) CZ300513B6 (ru)
DE (2) DE19937304C2 (ru)
EA (1) EA007531B1 (ru)
EE (1) EE04928B1 (ru)
ES (1) ES2231243T3 (ru)
HK (1) HK1046854B (ru)
HR (1) HRP20020117A2 (ru)
HU (1) HUP0202397A3 (ru)
IL (1) IL148057A (ru)
MX (1) MXPA02001373A (ru)
MY (1) MY129668A (ru)
NO (1) NO20020605L (ru)
NZ (1) NZ517367A (ru)
PL (1) PL198483B1 (ru)
PT (1) PT1207884E (ru)
SK (1) SK285587B6 (ru)
TR (1) TR200200359T2 (ru)
TW (1) TWI285550B (ru)
UA (1) UA73137C2 (ru)
WO (1) WO2001010425A2 (ru)
YU (1) YU8302A (ru)
ZA (1) ZA200200997B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
AU2002359458A1 (en) * 2001-12-12 2003-06-23 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1648466A1 (en) * 2003-07-07 2006-04-26 Boehringer Ingelheim International GmbH Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0765668B1 (fr) * 1995-09-07 1999-03-17 L'oreal Extrait d'iridacees et compositions le contenant
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
JP3483893B2 (ja) * 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
WO2001010425A2 (de) 2001-02-15
BG65366B1 (bg) 2008-04-30
BG106391A (bg) 2002-09-30
AU6992800A (en) 2001-03-05
CA2378428A1 (en) 2001-02-15
MY129668A (en) 2007-04-30
ATE281168T1 (de) 2004-11-15
NZ517367A (en) 2004-09-24
EA007531B1 (ru) 2006-10-27
HUP0202397A2 (en) 2002-10-28
HUP0202397A3 (en) 2006-07-28
SK1972002A3 (en) 2002-06-04
EE04928B1 (et) 2007-12-17
CN1166361C (zh) 2004-09-15
AU777709B2 (en) 2004-10-28
DE19937304A1 (de) 2001-03-15
ES2231243T3 (es) 2005-05-16
PT1207884E (pt) 2004-12-31
KR20020016947A (ko) 2002-03-06
CN1370069A (zh) 2002-09-18
NO20020605D0 (no) 2002-02-07
CZ300513B6 (cs) 2009-06-03
PL364049A1 (en) 2004-12-13
MXPA02001373A (es) 2002-07-30
PL198483B1 (pl) 2008-06-30
EP1207884B1 (de) 2004-11-03
HK1046854A1 (en) 2003-01-30
EP1207884A2 (de) 2002-05-29
SK285587B6 (sk) 2007-04-05
KR100713573B1 (ko) 2007-05-02
IL148057A0 (en) 2002-09-12
YU8302A (sh) 2004-12-31
TR200200359T2 (tr) 2002-05-21
EE200200061A (et) 2003-04-15
TWI285550B (en) 2007-08-21
HK1046854B (zh) 2005-02-25
JP2003506403A (ja) 2003-02-18
DE19937304C2 (de) 2003-08-21
IL148057A (en) 2008-04-13
WO2001010425A3 (de) 2002-02-07
CZ2002497A3 (cs) 2002-06-12
DE50008527D1 (de) 2004-12-09
CA2378428C (en) 2009-10-20
BR0013009A (pt) 2002-04-30
UA73137C2 (en) 2005-06-15
ZA200200997B (en) 2002-10-30
HRP20020117A2 (en) 2003-10-31
NO20020605L (no) 2002-02-07
AR025078A1 (es) 2002-11-06

Similar Documents

Publication Publication Date Title
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
EA200200208A1 (ru) Синергитическая композиция
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
NO924619D0 (no) (+)-alfa-(2,3-dimetoksyfenyl)-1-(2-(4-fluorfenyl)ethyl)-4-piperidinmetanol
TR199903280T2 (xx) Sertralin tuzlar� ve sertralinin tutmal�-bo�altma dozaj bi�imleri.
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
EA200200571A1 (ru) Новая композиция и ее применение
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
UA37259C2 (ru) Активное вещество для получения лекарственных средств для лечения дисфункциональных маточных кровотечений
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
SE9802208D0 (sv) Novel compounds
BR9809848A (pt) Composição
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
EA200200303A1 (ru) Синергетические комбинации антагониста рецептора nk1 и структурного аналога гамк
PT1147105E (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU